Lipella Pharmaceuticals Inc.
LIPO
$0.31
$0.0311.80%
OTC PK
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -33.00% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -33.00% | |||
| Cost of Revenue | -8.92% | -20.32% | |||
| Gross Profit | -2.28% | 18.42% | |||
| SG&A Expenses | -15.10% | 40.54% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -11.71% | -0.95% | |||
| Operating Income | 6.07% | -2.17% | |||
| Income Before Tax | 5.53% | -1.61% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 5.53% | -1.61% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 5.53% | -1.61% | |||
| EBIT | 6.07% | -2.17% | |||
| EBITDA | 6.07% | -2.17% | |||
| EPS Basic | 10.57% | 51.46% | |||
| Normalized Basic EPS | 10.59% | 51.46% | |||
| EPS Diluted | 9.68% | 51.56% | |||
| Normalized Diluted EPS | 10.59% | 51.46% | |||
| Average Basic Shares Outstanding | 5.67% | 109.32% | |||
| Average Diluted Shares Outstanding | 5.67% | 109.32% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||